Abstract:Prostate cancer (PCa) testing is currently based on measurement of serum prostate-specific antigen levels and digital rectal examination, which are limited by a low predictive value and the adverse effects associated with overdiagnosis and overtreatment. Recent studies have reported that the abnormal expression of microRNAs (miRNAs) is associated with the mechanism underlying the development of PCa. Thus, the aim of the present study was to investigate the effects of miR-30e and its target gene, M3 muscarinic acetylcholine receptor (CHRM3), on the adhesion, migration, invasion and cell cycle distribution of PCa cells via the mitogen-activated protein kinase (MAPK) signaling pathway. The differentially expressed genes were screened in the Gene Expression Omnibus database from a gene expression microarray (GSE55945) of PCa. PCa tissues and adjacent tissues were collected from patients with PCa. The PC-3 and DU145 human PCa cell lines were treated with activator, inhibitor and siRNAs. The effects of miR-30e on cell adhesion, migration, invasion and cell cycle distribution with the involvement of CHRM3 and the MAPK signaling pathway were investigated. The bioinformatics results demonstrated that the CHRM3 gene and the MAKP signaling pathway were involved in the progression of PCa, and has-miR-30e was selected for further study. The levels of miR-30e were significantly downregulated, while the levels of CHRM3 were obviously upregulated in PCa. CHRM3 was verified as a target gene of miR-30e. Upregulation of miR-30e and downregulation of CHRM3 decreased the levels of p-P38, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase, p-c-fos and p-c-JUN, cell adhesion, migration and invasion ability, and the number of cells in the S phase, while they increased the number of cells in the G0 and G1 phases. The findings of the present study suggest that miR-30e inhibited the adhesion, migration, invasion and cell cycle entry of PCa cells by suppressing the activation of the MAPK signaling pathway and inhibiting CHRM3 expression. Thus, miR-30e may serve as a candidate target for the treatment of PCa.

MiR-1 Inhibits Prostate Cancer PC3 Cells Proliferation Through the Akt/mTOR Signaling Pathway by Binding to C-Met

Nonconserved Mir‐608 Suppresses Prostate Cancer Progression Through RAC2/PAK4/LIMK1 and BCL2L1/caspase‐3 Pathways by Targeting the 3′‐utrs of RAC2/BCL2L1 and the Coding Region of PAK4

MicroRNA-107 Inhibits Proliferation of Prostate Cancer Cells by Targeting Cyclin E1.

miR-31-5p Regulates 14-3-3 ɛ to Inhibit Prostate Cancer 22RV1 Cell Survival and Proliferation via PI3K/AKT/Bcl-2 Signaling Pathway.

MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.

MiR-129 Inhibits Cell Proliferation and Metastasis by Targeting ETS1 Via PI3K/AKT/mTOR Pathway in Prostate Cancer

Mir-203 Inhibits Cell Proliferation and ERK Pathway in Prostate Cancer by Targeting IRS-1

MicroRNA‐487a‐3p Functions As a New Tumor Suppressor in Prostate Cancer by Targeting CCND1

MicroRNA-194 Regulates Cell Viability and Apoptosis by Targeting CDH2 in Prostatic Cancer

MiR-573 Inhibits Prostate Cancer Metastasis by Regulating Epithelial-Mesenchymal Transition.

MicroRNA-193a-3p Inhibits Cell Proliferation in Prostate Cancer by Targeting Cyclin D1

Mir-141 Inhibits Prostatic Cancer Cell Proliferation and Migration, and Induces Cell Apoptosis Via Targeting of RUNX1

MicroRNA-340 Inhibits Prostate Cancer Cell Proliferation and Metastasis by Targeting the MDM2-p53 Pathway.

MicroRNA-30e Inhibits Adhesion, Migration, Invasion and Cell Cycle Progression of Prostate Cancer Cells Via Inhibition of the Activation of the MAPK Signaling Pathway by Downregulating CHRM3

MiR-491-5p negatively regulates cell proliferation and motility by targeting PDGFRA in prostate cancer.

Mir-181a-5p Is Downregulated And Inhibits Proliferation And The Cell Cycle In Prostate Cancer

Oncogene Mir-106A Promotes Proliferation and Metastasis of Prostate Cancer Cells by Directly Targeting PTEN in Vivo and in Vitro

MicroRNA181c Inhibits Prostate Cancer Cell Growth and Invasion by Targeting Multiple ERK Signaling Pathway Components

MiR-142-3p Functions As an Oncogene in Prostate Cancer by Targeting FOXO1

MiR-146b Inhibits Autophagy in Prostate Cancer by Targeting the PTEN/Akt/mTOR Signaling Pathway.

MiR-203 Inhibits the Malignant Behavior of Prostate Cancer Cells by Targeting RGS17.